Señales en vivo de ELTX | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 may 2024 @ 16:00):

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases...

Stats
Volumen de hoy	25 177.00
Volumen promedio	61 981.00
Capitalización de mercado	82.68M
EPS	$-1.750 ( 2024-05-15 )
Próxima fecha de ganancias	( $-0.960 ) 2024-08-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.11
ATR14	$0.0580 (0.72%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-19	Chudnovsky Yekaterina	Buy	1 032 702	Pre-Funded Common Stock Purchase Warrant
2024-02-01	Piekos Brian	Buy	43 225	Stock Option (right to buy)
2024-02-01	Connelly Robert	Buy	225 137	Stock Option (right to buy)
2024-02-01	Haqq Christopher	Buy	28 200	Stock Option (right to buy)
2024-02-01	Demuth Peter	Buy	29 800	Stock Option (right to buy)

INSIDER POWER
100.00
Last 6 transactions
Buy: 1 359 406 \| Sell: 0

Elicio Therapeutics, Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Elicio Therapeutics, Inc. Finanzas

Annual	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-88.84

FY	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-88.84

FY	2020
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.930

FY	2019
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.505

Financial Reports:

No articles found.

Elicio Therapeutics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company\'s lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.